Albumedix announced its succession plan as Peter Rosholm, after 13 years as CEO, and handover the company’s leadership. Jonas Skjødt Møller is Rosholm’s successor as Chief Executive Officer effective July 1, 2020. Rosholm will stay operational with the company for a period and remain an active advisor and member of the Board of Directors, as the majority shareholder of the company.
Under Peter Rosholm’s leadership, Albumedix has transformed into a market-leading integrated life science company and the global leader of recombinant human albumin.
“From our center of excellence in Nottingham, we have been on an incredible global journey and a promising trajectory, which it has been my honor to direct since 2007. Building on a lasting legacy and history as pioneers within albumin manufacturing and innovation, the company stands stronger than ever and is uniquely positioned to accelerate its global impact. Jonas has been an integral part of Albumedix´ development, success and culture, and is an extremely talented individual. I see no one better suited to take the company forward,” Rosholm said.
“The Board remains extremely appreciative of Peter’s exemplary leadership over many years, which has built a strong organization and solidified Albumedix’ market-leading position. We are delighted that we will continue to benefit from his experience in an operational role for a period and in an advisory role going forward,” Albumedix Board of Directors, Chairman, Don DeBethizy, said.
Jonas Skjødt Møller’s succession as CEO has been in planning for some time, after the board unanimously supported the decision. Jonas brings operational experience from the biopharmaceutical industry and from 8 years within the business. His knowledge of the company stems from having held an array of positions, including within the labs and on the front-line with customers, and he has been a critical co-driver behind the recent growth, together with the Executive Leadership Team.
“I am honored to take Albumedix forward as CEO, solidifying our position as world leaders in recombinant human albumin. The opportunities ahead are game changing, especially today as we witness the need globally for rapidly scalable vaccine platforms and advanced therapies to significantly transform lives. The vision is to empower excellence: in how we as a business operate and create products and services of the highest quality; but also to enable our customers and partners to excel in the development of transformative therapies, and thereby support life sciences and patients equally. I’m excited to spearhead this new wave of growth, take the reins and build on a shared legacy with an ambition to enable superior therapies worldwide,” Skjødt Møller said.